US2259698A
(en)
|
1938-05-07 |
1941-10-21 |
Rare Chemicals Inc |
Physiologically effective substance and process of preparing same
|
US2594323A
(en)
|
1948-07-22 |
1952-04-29 |
Upjohn Co |
24-substituted delta 5-cholene-3, 24-diols
|
US3079385A
(en)
|
1961-01-24 |
1963-02-26 |
Roussel Uclaf |
Novel process of preparation of polyhydroxylated pregnanes
|
US3206459A
(en)
|
1962-10-19 |
1965-09-14 |
Syntex Corp |
10alpha-pregnan-19-ol derivatives
|
JPS5324071B2
(sr)
|
1974-04-30 |
1978-07-18 |
|
|
US4071625A
(en)
|
1974-05-13 |
1978-01-31 |
Richardson-Merrell Inc. |
19-Oxygenated-5α-androstanes for the enhancement of libido
|
CH628907A5
(en)
|
1975-10-10 |
1982-03-31 |
Hoffmann La Roche |
Process for the preparation of 24,25-dihydroxycholesterol derivatives
|
JPS5840960B2
(ja)
|
1976-12-28 |
1983-09-08 |
帝人株式会社 |
ヒドロキシコレステロ−ル立体異性体間の相互変換法
|
JPS54163565A
(en)
|
1978-06-09 |
1979-12-26 |
Teijin Ltd |
24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
|
JPS5735597A
(en)
|
1980-08-13 |
1982-02-26 |
Teijin Ltd |
25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
|
JPS61254599A
(ja)
|
1985-05-07 |
1986-11-12 |
Sumitomo Pharmaceut Co Ltd |
コレステロ−ルのフツ素誘導体
|
JPS62187485A
(ja)
|
1986-02-13 |
1987-08-15 |
Teijin Ltd |
24,25−エポキシコレステロ−ル類の製造法
|
US5232917A
(en)
|
1987-08-25 |
1993-08-03 |
University Of Southern California |
Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
DE69435286D1
(de)
|
1993-05-24 |
2010-05-20 |
Purdue Pharma Ltd |
Verfahren und zusammensetzungen zum hervorrufen von schlaf
|
IL110309A0
(en)
|
1993-07-15 |
1994-10-21 |
Univ Kentucky Res Found |
A method of protecting against neuron loss
|
DE4338316A1
(de)
|
1993-11-10 |
1995-05-11 |
Jenapharm Gmbh |
Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
|
JP4066272B2
(ja)
|
1994-02-14 |
2008-03-26 |
ユーロ‐セルティック エス. ア. |
Gaba受容体のアロステリックな調節のためのアンドロスタン及びプレグナン類
|
TW385308B
(en)
|
1994-03-04 |
2000-03-21 |
Merck & Co Inc |
Prodrugs of morpholine tachykinin receptor antagonists
|
US5595996A
(en)
|
1994-10-25 |
1997-01-21 |
Merck & Co., Inc. |
7-substituted 4-aza cholanic acid derivatives and their use
|
ATE198753T1
(de)
|
1994-11-23 |
2001-02-15 |
Cocensys Inc |
Androstan- und pregnanserien für die allosterische modulation des gaba-rezeptors
|
JPH08268917A
(ja)
|
1995-03-31 |
1996-10-15 |
D D S Kenkyusho:Kk |
癌組織への移行性の高い制癌剤
|
UA57706C2
(uk)
|
1995-06-06 |
2003-07-15 |
Косенсіз, Інк |
Нейроактивні стероїди ряду андростанів та прегнанів, фармацевтична композиція і спосіб лікування (варіанти)
|
US5792635A
(en)
|
1995-06-07 |
1998-08-11 |
Magainin Pharmaceuticals, Inc. |
Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
|
US6645953B2
(en)
|
1995-06-23 |
2003-11-11 |
Novo Nordisk A/S |
Meiosis regulating compounds
|
HUP9900454A3
(en)
|
1995-06-23 |
1999-11-29 |
Novo Nordisk As |
Meiosis regulating compounds and their use
|
WO1997003677A1
(en)
|
1995-07-24 |
1997-02-06 |
Trustees Of Boston University |
Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
|
US5888996A
(en)
|
1995-07-26 |
1999-03-30 |
Trustees Of Boston University |
Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
|
JPH09328498A
(ja)
|
1996-06-10 |
1997-12-22 |
Teijin Ltd |
24,25−ジヒドロキシコレステロールの製造法およびその合成中間体
|
AU3967297A
(en)
|
1996-08-01 |
1998-02-25 |
Cocensys, Inc. |
Use of gaba and nmda receptor ligands for the treatment of migraine headache
|
DE19635525A1
(de)
|
1996-08-20 |
1998-02-26 |
Schering Ag |
7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
|
CA2331299A1
(en)
|
1998-05-11 |
1999-11-18 |
Novo Nordisk A/S |
Substituted guanidines and diaminonitroethenes, their preparation and use
|
KR20010043558A
(ko)
|
1998-05-13 |
2001-05-25 |
한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 |
감수분열 조절 화합물
|
US8541600B2
(en)
|
1998-11-24 |
2013-09-24 |
Harbor Therapeutics, Inc. |
11-aza, 11-thia and 11-oxa sterol compounds and compositions
|
DE19917930A1
(de)
|
1999-04-15 |
2000-10-19 |
Schering Ag |
Ent-Steroide als selektiv wirksame Estrogene
|
US6376530B1
(en)
|
1999-05-10 |
2002-04-23 |
Merck & Co., Inc. |
Cyclic amidines useful as NMDA NR2B antagonists
|
GB9910934D0
(en)
|
1999-05-11 |
1999-07-14 |
Res Inst Medicine Chem |
Chemical compounds
|
CN1098273C
(zh)
|
1999-11-12 |
2003-01-08 |
中国科学院上海有机化学研究所 |
高立体选择性的合成24r,25-和24s,25-二羟基甾体化合物
|
GB0000228D0
(en)
|
2000-01-06 |
2000-03-01 |
Phytopharm Plc |
Fluoro substituted sapogenins and their use
|
GB0019290D0
(en)
|
2000-08-04 |
2000-09-27 |
Symphar Sa |
Methods for inducing apolipoprotein E secretion
|
GR1003861B
(el)
|
2000-12-29 |
2002-04-11 |
|
Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
|
GB0107822D0
(en)
|
2001-03-28 |
2001-05-23 |
Phytopharm Plc |
Sapogenin derivatives their synthesis and use methods based upon their use
|
DK1392713T3
(da)
|
2001-05-03 |
2008-02-18 |
Univ Chicago |
Lever-X-receptoragonister
|
US20070197484A1
(en)
|
2001-05-03 |
2007-08-23 |
Ching Song |
Method of treating disorder related to high cholesterol concentration
|
EP1450816A4
(en)
|
2001-11-08 |
2008-02-13 |
Univ Chicago |
METHOD FOR TREATING DISORDER IN CONNECTION WITH INCREASED CHOLESTERITE CONCENTRATION
|
US20030162758A1
(en)
|
2001-12-07 |
2003-08-28 |
Schwartz Daniel M. |
Treatment for age-related macular degeneration (AMD)
|
ATE424211T1
(de)
|
2002-03-27 |
2009-03-15 |
Phytopharm Plc |
Therapeutische verwendung von sapogeninen
|
CN102727501A
(zh)
|
2002-03-27 |
2012-10-17 |
菲特法姆股份有限公司 |
皂角苷配基及其衍生物的用途
|
GB0216621D0
(en)
|
2002-07-17 |
2002-08-28 |
Imaging Res Solutions Ltd |
Imaging compounds
|
US6933312B2
(en)
|
2002-10-07 |
2005-08-23 |
Agouron Pharmaceuticals, Inc. |
Pyrazole derivatives
|
US20060160853A1
(en)
|
2002-11-22 |
2006-07-20 |
Mccauley John A |
2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists
|
WO2004055201A2
(en)
|
2002-12-13 |
2004-07-01 |
Bayer Healthcare Ag |
Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
|
FR2850023B1
(fr)
|
2003-01-17 |
2007-04-06 |
Mapreg |
Medicaments pour le systeme nerveux
|
GB0403889D0
(en)
|
2004-02-21 |
2004-03-24 |
Univ Edinburgh |
Uses of er-beta modulators
|
WO2006037016A2
(en)
*
|
2004-09-27 |
2006-04-06 |
The Regents Of The University Of California |
Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
|
US20070032464A1
(en)
|
2004-10-08 |
2007-02-08 |
Shutsung Liao |
Methods of treating cancers
|
JP2008518935A
(ja)
|
2004-11-01 |
2008-06-05 |
セオ ホン ユー |
筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
|
AU2007217366A1
(en)
|
2006-02-27 |
2007-08-30 |
The Regents Of The University Of California |
Oxysterol compounds and the hedgehog pathway
|
CN101164540A
(zh)
|
2006-08-03 |
2008-04-23 |
中山大学 |
海洋甾体化合物在制备治疗神经元损伤药物中的应用
|
GB0619860D0
(en)
|
2006-10-06 |
2006-11-15 |
Birkeland Innovasjon As |
Treatment of insulin resistance and disorders associated therewith
|
WO2008057468A1
(en)
|
2006-11-02 |
2008-05-15 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
MX2009005335A
(es)
|
2006-11-21 |
2009-06-08 |
Umecrine Ab |
El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc.
|
AU2008331808B2
(en)
|
2007-03-16 |
2014-08-21 |
The Regents Of The University Of California |
Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling
|
NZ599643A
(en)
|
2007-06-20 |
2013-11-29 |
Auspex Pharmaceuticals Inc |
Substituted N-aryl pyridinones as fibrotic inhibitors
|
GB0712494D0
(en)
|
2007-06-27 |
2007-08-08 |
Isis Innovation |
Substrate reduction therapy
|
CA2703497A1
(en)
|
2007-11-06 |
2009-05-14 |
N.V. Organon |
A method of hormone suppression in humans
|
WO2009090063A1
(en)
|
2008-01-16 |
2009-07-23 |
Jado Technologies Gmbh |
Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
|
CA2711487A1
(en)
|
2008-01-25 |
2009-07-30 |
Merck Sharp & Dohme Corp. |
Quinolizidinone m1 receptor positive allosteric modulators
|
EP2296658A4
(en)
|
2008-05-09 |
2014-01-15 |
Univ Emory |
ANTAGONISTS OF NMDA RECEPTORS USEFUL FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS
|
WO2010065709A2
(en)
|
2008-12-03 |
2010-06-10 |
Amin Khan |
Hydroxamic acid derivatives, preparation and therapeutic uses thereof
|
US20120040916A1
(en)
|
2008-12-22 |
2012-02-16 |
Massachusetts Institute Of Technology |
Molecular inhibitors of the wnt/beta-catenin pathway
|
US20110319416A1
(en)
|
2009-01-28 |
2011-12-29 |
Emory University |
Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
|
US8829213B2
(en)
|
2009-07-29 |
2014-09-09 |
The University Of Chicago |
Liver X receptor agonists
|
WO2011028794A2
(en)
|
2009-09-01 |
2011-03-10 |
Lazarus Therapeutics, Inc. |
Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
|
FR2953138B1
(fr)
|
2009-12-02 |
2015-10-16 |
Assist Publ Hopitaux Marseille |
Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
|
WO2011092127A1
(en)
|
2010-01-26 |
2011-08-04 |
Bayer Schering Pharma Aktiengesellschaft |
14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring
|
KR101692275B1
(ko)
|
2010-02-11 |
2017-01-04 |
노오쓰웨스턴 유니버시티 |
2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
GB201008047D0
(en)
|
2010-05-14 |
2010-06-30 |
Ge Healthcare Ltd |
Method of synthesis
|
US20120035156A1
(en)
|
2010-08-09 |
2012-02-09 |
Daniela Alberati |
Combination of glyt1 compound with antipsychotics
|
US8969525B2
(en)
|
2010-11-09 |
2015-03-03 |
Enzo Life Sciences, Inc. |
Hydroxycholesterol immunoassay
|
WO2012142039A1
(en)
|
2011-04-15 |
2012-10-18 |
University Of North Dakota |
Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
|
US20140335050A1
(en)
|
2011-05-27 |
2014-11-13 |
The General Hospital Corporation |
Methods, compositions, and kits for the treatment of cancer
|
EP2736919A4
(en)
|
2011-07-29 |
2015-01-14 |
Univ California |
NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
|
CN107936076B
(zh)
*
|
2011-09-08 |
2021-10-15 |
萨奇治疗股份有限公司 |
神经活性类固醇、组合物、及其用途
|
MX360706B
(es)
|
2011-10-07 |
2018-11-14 |
Takeda Pharmaceuticals Co |
Compuestos de 1-arilcarbonil-4-oxi-piperidina utiles para el tratamiento de enfermedades neurodegenerativas.
|
US20150291654A1
(en)
*
|
2011-10-14 |
2015-10-15 |
Sage Therapeutics, Inc. |
3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
|
US20150119327A1
(en)
|
2012-04-25 |
2015-04-30 |
The Regents Of The University Of California |
Drug screening platform for rett syndrome
|
WO2014025942A1
(en)
|
2012-08-09 |
2014-02-13 |
Emory University |
Nmda receptor modulators and uses related thereto
|
SI2935307T1
(en)
|
2012-12-18 |
2018-08-31 |
Washington University |
Non-reactive 19-alkoxy-17-substituted steroids useful in therapeutic procedures
|
CN112552364A
(zh)
|
2013-01-23 |
2021-03-26 |
司菲埃拉制药私人有限公司 |
用于线粒体生物发生和与线粒体功能障碍或耗竭相关的疾病的新颖11β-羟基类固醇化合物
|
SG11201505934XA
(en)
|
2013-01-29 |
2015-09-29 |
Naurex Inc |
Spiro-lactam nmda receptor modulators and uses thereof
|
BR112015022934A8
(pt)
*
|
2013-03-13 |
2019-11-26 |
Sage Therapeutics Inc |
esteróides neuroativos, composições e usos destes
|
JP6255082B2
(ja)
*
|
2013-03-13 |
2017-12-27 |
セージ セラピューティクス, インコーポレイテッド |
神経刺激性ステロイドおよびその使用方法
|
ES2751457T3
(es)
|
2013-09-25 |
2020-03-31 |
Van Andel Res Institute |
Glucocorticoides altamente potentes
|
EP3157528B1
(en)
|
2014-06-18 |
2023-09-13 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
US10238664B2
(en)
|
2014-07-09 |
2019-03-26 |
Duke University |
Compositions and methods for the repair of myelin
|
KR20170065637A
(ko)
|
2014-10-07 |
2017-06-13 |
세이지 테라퓨틱스, 인크. |
신경활성 화합물 및 그의 사용 방법
|
JP2018519351A
(ja)
|
2015-07-06 |
2018-07-19 |
セージ セラピューティクス, インコーポレイテッド |
オキシステロールおよびそれらの使用の方法
|
KR20180026742A
(ko)
|
2015-07-06 |
2018-03-13 |
세이지 테라퓨틱스, 인크. |
옥시스테롤 및 그의 사용 방법
|
AU2016289965B2
(en)
|
2015-07-06 |
2021-09-09 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
GB2557875A
(en)
|
2015-09-02 |
2018-07-04 |
Univ Swansea |
Diagnostic methods and kits
|
BR112018070123A2
(pt)
|
2016-04-01 |
2019-02-05 |
Sage Therapeutics Inc |
oxiesterós e métodos de uso dos mesmos
|
WO2017193046A1
(en)
|
2016-05-06 |
2017-11-09 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
LT3481846T
(lt)
|
2016-07-07 |
2021-08-25 |
Sage Therapeutics, Inc. |
11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles
|
JP7065825B2
(ja)
|
2016-07-11 |
2022-05-12 |
セージ セラピューティクス, インコーポレイテッド |
C7、c12、およびc16置換神経刺激性ステロイドおよびそれらの使用方法
|
MA46351A
(fr)
|
2016-09-30 |
2021-06-02 |
Sage Therapeutics Inc |
Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
|
KR20230051723A
(ko)
|
2016-10-18 |
2023-04-18 |
세이지 테라퓨틱스, 인크. |
옥시스테롤 및 그의 사용 방법
|
CN115181153A
(zh)
|
2016-10-18 |
2022-10-14 |
萨奇治疗股份有限公司 |
氧甾醇及其使用方法
|
US11969506B2
(en)
|
2017-03-15 |
2024-04-30 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
AU2018288883B2
(en)
|
2017-06-23 |
2022-06-02 |
Intercept Pharmaceuticals, Inc. |
Methods and intermediates for the preparation of bile acid derivatives
|
KR20200085837A
(ko)
|
2017-11-10 |
2020-07-15 |
마리누스 파마슈티컬스 인코포레이티드 |
유전적 간질 질환 치료에 사용하기 위한 가낙솔론의 용도
|
TW202110824A
(zh)
|
2019-05-24 |
2021-03-16 |
美商賽吉醫療公司 |
化合物、組合物及使用方法
|